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Abstract Conjugated linoleic acid (CLA) is thought to
have anti-proliferative and anti-inflammatory properties,
but its effect on cancer cachexia is unknown. Two effects
were here investigated: that of CLA on inflammatory
mediator production in human lung cancer cells, and that of
reduced mediators on the myogenic differentiation of
murine muscle C2C12 cells. The latter cells were grown in
medium conditioned by human lung cancer A427 cells,
with or without CLA, to mimic only the effect of molecules
released from the tumor ‘‘in vivo’’, excluding the effect of
host-produced cachectic factors. The results obtained show
that CLA was found to reduce the production of tumor
necrosis factor-a, interleukin (IL)-1b and prostaglandin E2
(PGE2), but had no effect on IL-6 production. The mech-
anisms underlying the effect of CLA on cytokine or PGE2
release in A427 cells are probably mediated by activation
of peroxisome proliferator-activated receptor (PPAR)a,
which increased at 24 h CLA treatment. In turn, the
reduced content of inflammatory mediators in medium
conditioned by A427 cells, in the presence of CLA,
allowed muscle cells to proliferate, again by inducing
PPAR. The involvement of PPARa was demonstrated by
treatment with the antagonist MK-886. The findings dem-
onstrate the anti-inflammatory and myogenic action of
CLA and point to its possible application as a novel dietary
supplement and therapeutic agent in inflammatory disease
states, such as cachexia.
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PGE2 Prostaglandin E2
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Introduction
One of the commonest manifestations of advanced malig-
nant disease is the development of cancer cachexia, which
is responsible for about 20 % of cancer-related deaths.
Associated abnormalities include anorexia, weight loss,
muscle loss and atrophy, anemia, and alterations in car-
bohydrate, lipid and protein metabolism [1–3]. Muscle
wasting is the most important feature of cancer cachexia,
and the principal cause of morbidity and mortality in
cancer patients [4]. Skeletal muscle is a highly adaptable
tissue, which responds to physiological challenges by
changing size and metabolism, undergoing changes in
growth and development under the strict control of myo-
genic regulatory factors [5].
Although cachectic factor(s) have long been sought, and
considerable scientific effort and economic resources have
been devoted to their investigation, the picture is still
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fragmentary. Experimental research and clinical studies
have demonstrated that cytokines are involved in inducing
cachexia [6, 7], although the results require careful inter-
pretation. Episodic administration of tumor necrosis factor
(TNF) has proved unsuccessful at inducing cachexia in
experimental animals; repetitive TNF administration ini-
tially induces a cachectic effect, but tolerance to the
cytokine soon develops and food intake and body weight
return to normal. Escalating doses of TNF have been
shown necessary to maintain the cachectic effect [3].
Treatment with anti-mouse interleukin (IL)-6 antibody,
or with nonpeptide IL-6 receptor antagonist, successfully
reversed the key parameters of cachexia in colon-adeno-
carcinoma-bearing mice [8, 9]. Conversely, studies on
incubated rat skeletal muscle have clearly shown that IL-6
has no direct effect on muscle proteolysis [10]. IL-1b
production in human and animal cancer cell lines is well
documented, and patients with IL-1b-producing tumors
generally have a poor prognosis [11]. This cytokine is also
reported to be responsible for enhanced protein degradation
in rats, in which repeated administration of IL-1b induced
anorexia and weight loss [11].
Since cancer cachexia is regarded as a chronic inflam-
matory condition, in which pharmacological and nutritional
interventions aimed at increasing muscle mass and weight
are of limited benefit [12], the current strategies for man-
aging this condition focus on the use of agents with anti-
inflammatory and nutritional properties. Conjugated lino-
leic acid (CLA) comprises a group of positional and geo-
metric isomers of linoleic acid, found naturally in meat and
dairy products from ruminant animals. It has shown
promise both in reducing inflammation and as an anti-
carcinogenic agent [13, 14]. CLA is formed in the rumen
during a process of bacterial biohydrogenation of linoleic
acid. Although 28 different isomers of CLA exist, the
c9,t11 form accounts for more than 90 % of the CLA
intake in the human diet [13]. The health benefits deriving
from CLA have been attributed to the two main isomer
forms, c9,t11 and t10,c12; these are the predominant bio-
logically active forms and exhibit numerous physiological
properties [15, 16]. The health-related effects of CLA have
been confirmed in numerous animal and human-interven-
tion studies; they include anti-carcinogenic, anti-athero-
genic, anti-diabetogenic, and immunomodulatory actions
[17–19]. In vitro studies have shown CLA to inhibit pro-
liferation of several human tumor cell lines, in a dose- and
time-dependent manner [17, 20, 21].
It has been suggested that the anti-carcinogenic prop-
erties of CLA stem from its anti-inflammatory properties,
as the acid negatively regulates the expression of pro-
inflammatory genes such as TNF-a, IL-1b, and IL-6 [22].
Due to its anti-proliferative and potentially anti-inflam-
matory properties, CLA might be a novel dietary
supplement for patients suffering from muscle wasting in
chronic inflammatory-related disease, particularly cancer
cachexia.
CLA is not universally considered to be of use as a
supplement in cachexia patients [23]. The addition of
c9,t11-CLA-rich oil to the diet did not ameliorate wasting
in mice with cancer cachexia [24]. However, other studies
have shown that CLA can preserve muscle mass in tumor-
bearing cachectic animals, decreasing skeletal muscle
wasting and reducing the catabolic effects of TNF-a, and
have suggested that it may have overall protective prop-
erties in cachexia [25, 26]. In particular, one study reported
CLA to possess specific tumor-related effects on myogenic
and inflammatory gene expression, in an in vitro human co-
culture model comprising a pancreatic tumor cell line and
human primary muscle cells [27].
The present study investigated the effects of CLA on the
proliferation and production of inflammatory mediators in
human lung cancer A427 cells. It also examined the effects
of the secretion products of cancer cells, both treated and
untreated with CLA, on the myogenic differentiation of
murine muscle C2C12 cells.
Materials and Methods
A427 Cell Culture Conditions
Human lung A427 cells (ATCC, MD, USA) were cultured
(20,000 cells/cm2) in DMEM/F12 medium supplemented
with 2 mM glutamine, 1 % antibiotic/antimycotic solution
and 10 % FBS (medium A).
Treatment of A427 Cells with CLA
CLA was prepared in horse serum (HS) at a concentration
of 5 mM. A mixture of the two principal CLA isomers,
c9,t11 and t10,c12 (Sigma, MO, USA) was used. Twenty-
four hours after cell seeding, medium A was removed and
replaced with DMEM/F12 medium supplemented with
2 mM glutamine, 1 % antibiotic/antimycotic solution, 2 %
HS (medium B), and CLA (final concentration 5 or
50 lM). In control cells, a quantity of HS equivalent to the
highest dose administered with CLA was added to the cell
culture, in addition to the 2 % HS present in the medium B.
Twenty-four hours after CLA or HS addition, the culture
media were collected, pooled, and centrifuged at 2,800g for
10 min (centrifuge J6B Beckman Culture, CA, USA) at
room temperature. The resulting medium was used as
conditioned medium in which to culture C2C12 cells; it
was also used to determine pro-cachectic factor production
and lactate dehydrogenase (LDH) release. Cells were
washed with PBS, trypsinized and centrifuged at 900g for
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10 min (centrifuge J6B Beckman Culture, CA, USA) for
the assays listed below.
Treatment of A427 Cells with CLA and MK886
A427 cells were divided into four groups: (1) control cells;
(2) CLA group: cells treated with 5 lM CLA; (3) MK886
group: cells treated with 5 lM MK886 dissolved in
DMSO; (4) CLA plus MK886 group: cells treated with
both substances. After 24 h, in all groups cells were tryp-
sinized, centrifuged at 900g (centrifuge J6B Beckman
Culture, CA, USA) for 10 min, and cell proliferation was
evaluated; the culture medium was used to evaluate the
production of TNF-a and prostaglandin E2 (PGE2), and to
culture C2C12 cells.
C2C12 Cell Culture Conditions
Murine muscle C2C12 cells (ATCC, MD, USA) were
seeded at 6,000 cells/cm2 in medium A and maintained for
4 days. After this time, to induce differentiation into
myotubes, medium A was removed and replaced with
medium B, in which the C2C12 cells were maintained for a
further 3 days. Cells were then subdivided into five groups:
group I (Tdiff): cells grown in medium B; group II (con-
trol): cells grown in medium conditioned by A427 cells;
group III (5 lM CLA): cells grown in medium conditioned
by A427 cells treated with 5 lM CLA; group IV (MK886):
cells grown in medium conditioned by A427 cells treated
with 5 lM MK886; group V (MK886 ? CLA): cells
grown in medium conditioned by A427 cells treated with
5 lM CLA plus 5 lM MK886.
Cells and culture media of these groups were analyzed
after 1 or after 4 days. After medium removal, cells were
maintained frozen until use. The culture medium was
centrifuged at 2,800g (centrifuge J6B Beckman Culture,
CA, USA) for 10 min at 4 C and used to determine LDH
release.
Cell Growth and Viability
The number of A427 cells in the monolayer and that in the
culture medium were evaluated using a Burker chamber,
and expressed as cells/cm2. For both A427 and C2C12
cells, viability was evaluated by determining LDH release,
as described elsewhere [28].
Immunofluorescence Staining
To evaluate production of myosin and myofibrillar struc-
tures, C2C12 cells were washed with PBS, fixed with
acetone and methanol (1:1) at 20 C for 20 min and kept at
4 C until use. Cells were then permeabilized with 0.1 %
Triton X-100 in PBS and incubated with the monoclonal
anti-skeletal (fast) myosin antibody (1:400 in PBS-Triton
0.1 %) (Sigma, MO, USA) overnight at 4 C. After
washing in PBS-Triton 0.1 % and then in PBS alone, cells
were incubated with the appropriate Cy3-conjugated sec-
ondary antibody (1:1000) (GE Healthcare, UK) for 1 h at
room temperature.
To visualize nuclei, cells were stained with Hoechst dye
for 20 min. After incubation, cells were thoroughly washed
with bidistilled H2O and mounted with glycerol/PBS (1:1).
Fluorescence-labeled cells were viewed using a fluores-
cence reverted microscope, and photographed using a 932
lens (Zeiss, Germany). For image processing, Zeiss Axio-
Vision software was used.
Western Blot Analysis
A427 cells were suspended in a lysis buffer containing
20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA,
1 mM PMSF, 0.015 mg/ml leupeptin, 0.1 % NP-40 sub-
stitute, and 1 mM Na-orthovanadate. Suspensions were
kept on ice for 30 min. C2C12 cells were rubberized and
suspended in a RIPA buffer containing 50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 1 % NP-40 substitute, 0.5 %
Na-deoxycholate, 0.1 % SDS, 1 mM PMSF, 1 mM Na-ortho-
vanadate and 0.015 mg/ml leupeptin. Suspensions of both
cell types were kept on ice for 10 min and sonicated. Forty
microgram of cell proteins were separated by SDS–poly-
acrylamide gel electrophoresis, then electrotransferred to a
polyvinylidene difluoride (PVDF) membrane, which was
then blocked overnight with TBS containing 5 % non-fat
dry milk. The membrane was then rinsed and treated with
polyclonal anti-PPARa, anti-PPARb, or anti-PPARc anti-
bodies (Santa-Cruz Biotechnology Inc., CA, USA), and
monoclonal anti-NF-kBp65, anti-cyclooxygenase (COX)-
2, anti-skeletal (fast) myosin, anti-b-actin or anti-a-tubulin
antibodies (Sigma, MO, USA). Protein bands were visu-
alized using a chemiluminescent detection system (Immun-
StarTM HRP Luminol/Enhancer, Bio-Rad Laboratories
Inc., CA, USA).
Real-Time PCR
A427 cells were processed to determine PPAR expression
by real-time PCR. Total RNA was extracted from the cells
using the NucleoSpin RNA II Kit (Macherey–Nagel GmbH
& Co. KG, Germany). Real-time PCR was run with single-
stranded cDNA prepared from total RNA (1 lg) using a
High-Capacity cDNA Archive kit (Applied Bio Systems,
CA, USA). The forward (FW) and reverse (RV) primers
were designed using the Beacon Designer software
package (Bio-Rad Laboratories Inc., CA, USA). Twenty-
five microliters of a PCR mixture, containing cDNA
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template equivalent 40 ng of total RNA, 5 pmol each of
forward and reverse primers, and 29 IQ SYBR Green
SuperMix (Bio-Rad Laboratories Inc., CA, USA), were
amplified in an iCycler PCR instrument (Bio-Rad Labo-
ratories Inc., CA, USA) with an initial 10 min melt at
95 C, followed by 35–40 cycles at 95 C for 40 s,
annealing temperature for each primer set for 40 s, and
72 C for 40 s. Each sample was tested in duplicate, and
threshold cycle (Ct) values were averaged. The variation in
expression was defined as the relative expression in cells
treated with CLA versus that in control cells, calculated as
2-DDCt, where DCt = CtCLA – CtGAPDH and DDCt =
DCtCLA – DCtcontrol.
Chemical Analysis
TNF-a, IL-1b and IL-6 were evaluated by the Enzyme
Linked Immuno Sorbent Assay (Bender Medsystems,
Austria), while PGE2 was evaluated with an Enzyme
Immunoassay Kit (Oxford Biomedical Research, MI,
USA).
Protein Determination
Protein concentrations in A427 and C2C12 cell lysates
were measured using the Protein Assay Kit 2, following the
manufacturer’s instructions (Bio-Rad Laboratories Inc.,
CA, USA).
Statistical Analysis
All data are expressed as mean ± SD differences between
group means were assessed by analysis of variance
followed by a post hoc Newman-Keuls test or by the
Student’s t test.
Results
Effect of CLA on Human Lung Cancer A427 Cells
After 24 h, only the highest concentration of CLA (50 lM)
significantly reduced the number of cells, whereas the
lowest concentration (5 lM) left cell numbers similar to
control values (Fig. 1). Neither concentration of CLA
induced death, by necrosis or by apoptosis, as demonstrated
by LDH release in the medium and by cytofluorimetric
analysis (data not shown). For subsequent determinations,
only the 5 lM CLA concentration was used, in order to
avoid as far as possible any interference from decreased
cell proliferation.
Evaluation of cytokines in the culture medium (Fig. 2)
shows that CLA caused a significant decrease of TNF-a
and IL-1b versus control cells at 24 h, with no significant
decrease of IL-6. Figure 2 also shows that the release of
PGE2 in the culture medium was lower in cells treated with
CLA than in control cells.
Effect of Medium Conditioned by A427 Cells
on Murine Muscle C2C12 Cells
Medium conditioned for 24 h by A427 cells, untreated or
treated with CLA, did not affect the viability of C2C12 cells,
as evidenced by LDH determination in the culture medium
(data not shown). Figure 3 shows the differentiation degree
of C2C12 cells, grown for 1 or for 4 days in conditioned
medium; number and size of myotubes were evidenced by
immunofluorescence staining. At both 1 and 4 days, cells
grown in medium conditioned by A427 cells without CLA
showed little or no differentiation, compared to cells induced
to differentiate in the appropriate medium (Tdiff). Con-
versely, cells grown for 4 days in medium conditioned by
A427 cells treated with 5 lM CLA showed differentiation
increased in a time-dependent manner, reaching almost the
same degree of differentiation as cells grown in Tdiff. These
results were confirmed by evaluating myosin protein
expression, which significantly increased in C2C12 cells
grown for 4 days, in medium conditioned by A427 cells with
5 lM CLA, compared to control cells (Fig. 3).
PPAR Involvement
CLA is a PPAR ligand; these receptors were thus examined
in A427 cells, to investigate their possible involvement in
the CLA-induced decrease of cytokine and PGE2 produc-
tion. Figure 4 shows the PPAR trend, evaluated as mRNA
Fig. 1 Numbers of human lung cancer A427 cells, untreated or
treated with MK886, CLA or CLA ? MK886 for 24 h. Data are
mean ± SD from four experiments. Means with different letters are
significantly different from one another (p \ 0.05) as determined by
analysis of variance followed by post hoc Newman–Keuls analysis.
C control cells, CLA5 cells treated with 5 lM CLA, CLA50 cells
treated with 50 lM CLA, MK5 cells treated with 5 lM MK886,
CLA5 ? MK5 cells treated with 5 lM CLA ? 5 lM MK886
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(Fig. 4a) and protein expression (Fig. 4b). Both measures
of PPARa significantly increased versus control cells, 24 h
after treating A427 cells with CLA; conversely, PPARc
was unchanged, and PPARb showed a small but not sig-
nificant increase. As Fig. 4c shows, the protein expression
of NF-kB and COX-2 decreased in CLA-treated cells
versus controls cells after 24 h treatment.
Since PPARs are involved in reducing the inflammatory
process, their influence in regulating myosin production in
C2C12 cells was also examined. Figure 5 shows the PPAR
trend evaluated as mRNA (Fig. 5a, b) and as protein
(Fig. 5c): PPARa increased in C2C12 cells grown for
1 day in the culture medium of A427 cells treated with
CLA, whereas no variation was found at 4 days. PPARc
remained unchanged. As regards PPARb, a small but not
significant increase occurred after 1 day, and a significant
increase after 4 days.
To investigate the relation between PPARa and cytokine
and PGE2 production in A427 cells, a concentration of
PPARa-antagonist MK886 that does not affect cell pro-
liferation was administered to the cells (Fig. 1). The pres-
ence of MK886 prevented the reduction in TNF-a and
PGE2 production in A427 cells (Fig. 6), and the increase of
number and size of myotubes at both 1 and 4 days in
C2C12 cells, as evidenced by immunofluorescence staining
(Fig. 7).
Fig. 2 Concentrations of
TNF-a (a), IL-1b (b), IL-6
(c) and PGE2 (d) in medium of
human lung cancer A427 cells,
untreated or treated with CLA
for 24 h. Data are mean ± SD
from four experiments.
Student’s t test: *p \ 0.05,
control cells versus cells treated
with 5 lM CLA. C control
cells, CLA5 cells treated with
5 lM CLA
Fig. 3 Myosin content
evidenced by
immunofluorescence staining
and by Western blot analysis in
C2C12 murine myoblasts after 1
or 4 days of differentiation.
Differentiation was in medium
conditioned by human lung
cancer A427 cells, untreated or
treated with CLA for 24 h. For
Western blot analysis, 40 lg of
cell proteins were applied for
each lane. Tdiff cells grown in
medium b; C cells grown in
conditioned medium removed
from A427 cells untreated with
CLA; CLA5 cells grown in
conditioned medium removed
from A427 cells treated with
5 lM CLA
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Discussion
The study provides some insight into anti-inflammatory
and myogenic effects of the fatty acid CLA, and provides a
glimpse of its possible applications as a therapeutic agent
in inflammatory states underlying cachexia in cancer
patients. An in vitro model in which murine muscle C2C12
cells were grown in a medium conditioned by A427 human
lung cancer cells, exposed or not to CLA, was used to
mimic the effect of molecules released from the tumor
in vivo; this excluded any possible interference of the
effects of cachexia-mediator factors produced by the host.
One difficulty of in vivo research is that of differentiating
between effects due to pro-cachectic mediator factors
produced by the host, and those produced by cancer cells.
A mixture of c9,t11 and t10,c12 CLA isomers was used,
because they are the two major CLA forms present in the
diet and showing biological activity, even if c9,t11 CLA
constitutes up to 80 % of total CLA.
Exposing A427 cells to CLA reduced production of
TNF-a, IL-1b and PGE2, the reduction of PGE2 being due
to the decrease of COX-2. COX-2 is the pro-inflammatory
COX isoform, and is the rate-limiting enzyme in the syn-
thesis of prostaglandin PGE2 from arachidonic acid, one of
many fatty acids in the phospholipids of cell membranes
[29].
In murine muscle C2C12 cells, medium removed from
A427 cells not treated with CLA did not enable differentia-
tion to occur, as evidenced by the minimal number and size
of myotubes (immunofluorescence staining) and low level of
myosin expression (Western blot). Conversely, medium
conditioned by the presence of CLA, which had a lower
content of pro-inflammatory mediators than control medium,
allowed time-dependent differentiation to occur, evidencing
the importance of these factors on muscle cell modifications.
In our study, CLA mixture administered to A427 cells
enabled C2C12 cell differentiation, despite report that only
the c9,t11 isomer stimulates C2C12 cell differentiation [30].
It appears probable that, in the case of administration of a
CLA mixture, the effect of the c9,t11 isomer prevails.
There is considerable evidence from animal studies that
TNF-a plays a role in muscle loss in cancer cachexia,
although its role in the human condition is more ques-
tionable [31, 32]. Be that as it may, in our model the
reduction of PGE2, coupled with the reduction of cyto-
kines, regardless of cytokine type, was associated with
muscle cell differentiation. Mechanisms thought to under-
lie the effect of CLA on the decrease of cytokines or of
PGE2 in A427 cells were mediated by activation of
PPARa, which increased after 24 h of CLA treatment,
whereas the other PPARs did not show any statistically
significant variations.
The PPAR family comprises three ligand-activated
transcription factors: PPARa (NR1C1), PPARb (NR1C2),
and PPARc (NR1C3). All three PPARs play important
roles in regulating metabolic pathways, including those of
lipids and glucose. They are also involved in cell differ-
entiation, proliferation, and apoptosis pathways, and great
interest has been shown in their involvement in inflam-
matory processes. In particular, PPARa and PPARc inhibit
the activation of inflammatory gene expression, and may
negatively interfere with pro-inflammatory signaling path-
ways in vascular and inflammatory cells. The role played
by PPARb in regulating inflammation and immunity is
only now emerging [33].
PPARa agonist-induced activation has been shown to
inhibit a number of inflammatory pathways, including
TNF-a, inducible nitric oxide synthase, and COX-2, and
that it also inhibits infiltration of adhesion molecules and
cells into the tissues [34]. In this study, inhibition of
TNF-a, IL-1b and PGE2 by PPARa may have been mediated
by the decrease of p65 NF-kB, a hypothesis that would agree
with reports showing that increased PPARa expression
may inactivate TNF-a and COX-2, by inhibiting NF-kB.
Fig. 4 PPAR, COX-2 and NF-kBp65 expression in human lung
cancer A427 cells, untreated or treated with CLA for 24 h. PPARs
were analyzed by real-time PCR (a) and Western blot (b), COX-2 and
NF-kBp65 were analysed by Western blot (c). Data are mean ± SD
from three experiments. For real-time PCR (1 lg of cDNA), the
values of cells treated with CLA are referred to control value, taken as
1 (white bar). For Western blot (40 lg of cell proteins for each lane),
the densitometry value given for each protein is normalized to the
corresponding b-actin value and expressed as a percentage, setting the
control value (C) arbitrarily at 100. Student’s t test: *p \ 0.05, control
cells versus cells treated with 5 lM CLA. C control cells, CLA5 cells
treated with 5 lM CLA, C? positive control
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PPARa translocates from the cytosol to the nucleus, where
it binds with NF-kB to inhibit gene activation [35–37]. The
promoter regions of TNF-a, IL-1b and COX-2 genes
contain numerous transcription-factor binding sites,
including AP-1 and NF-kB. Several lines of evidence
suggest that PPARa exerts its anti-inflammatory effects
through negative regulation of NF-kB. In human aortic
smooth-muscle cells, PPARa has been shown to inhibit the
NF-kB transactivation function, by directly interacting with
the Rel homology domain of the p65 subunit, which
mediates DNA binding and dimerization activity [38].
PPARa ligands have also been found to upregulate
expression of the NF-kB inhibitor protein IkBa, in both
human aortic smooth-muscle cells and microglial cells,
leading to decreased DNA binding of NF-kB and gene
expression [39, 40].
Fig. 5 PPAR expression evidenced by real-time PCR (a, b) and
Western blot (c) in murine muscle C2C12 cells after 1 and 4 days of
differentiation. Differentiation was in medium conditioned by human
lung cancer A427 cells, untreated or treated with CLA for 24 h. Data
are mean ± SD from three experiments. For real-time PCR (1 lg of
cDNA), the values of cells treated with CLA are referred to the
control value, taken as 1 (white bar). For Western blot (40 lg of cell
proteins for each lane), the densitometry value given for each protein
is normalized to the corresponding b-actin value and expressed as a
percentage, setting the control value (C) arbitrarily at 100. For each
PPAR, means with different letters are significantly different from
one another (p \ 0.05) as determined by analysis of variance
followed by post hoc Newman–Keuls test. C cells grown in
conditioned medium removed from A427 cells untreated with CLA,
CLA5 cells grown in conditioned medium removed from A427 cells
treated with 5 lM CLA
Fig. 6 Concentrations of TNF-a (a) and PGE2 (b) in medium of
human lung cancer A427 cells, untreated or treated with CLA and
MK886 for 24 h. Data are means ± SD from three experiments. For
each panel, means with different letters are significantly different
from one another (p \ 0.05) as determined by analysis of variance
followed by post hoc Newman–Keuls test. C control cells, CLA5 cells
treated with 5 lM CLA, MK5 cells treated with 5 lM MK886,
CLA5 ? MK5, cells treated with 5 lM CLA ? 5 lM MK886
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The involvement of PPARa in reduction of inflamma-
tory factors induced by CLA was confirmed by using the
PPARa antagonist MK886, which enabled TNF-a and
PGE2 release to return to near control values in A427 cells,
while in C2C12 cells it permitted the anti-miogenic effect
of cytokines to occur. In our experimental model, PPARa
was involved not only in the effect of CLA on A427 cells,
but probably also in the effect of cytokines and PGE2 on
C2C12 cell differentiation. In the latter cells, medium
conditioned by A427 treated with CLA, and with a lower
content of pro-inflammatory factors than the medium of
untreated cells, caused an increase in PPARa, especially at
1 day, and in PPARb at 4 days. The increased PPAR
expression might be the cause of the increased myosin
content and increased number and size of myotubes, that
occurred in C2C12 cells grown in medium with reduced
inflammatory mediator content. The increase in PPAR
caused by the reduction of cytokines and PGE2 could also
be explained by the inhibition of NF-kB: TNF-a induces
muscle protein degradation by activating NF-kB, depen-
dently of ROS production or otherwise [31, 41].
The physical interaction between PPAR and the p65
subunit of NF-kB interferes with the activity of both
transcription factors [38, 40]. Because interaction between
PPAR and NF-kB leads to modulation of the inflammatory
response, a reciprocal effect of NF-kB on the PPAR
transactivation function is obviously to be expected.
In vitro assays have shown that translocation of NF-kB into
the nucleus represses PPAR transactivation of a PPRE-
driven promoter [42]. Increased PPAR expression may
explain the positive effect of reduced inflammatory medi-
ator content on increasing myosin content, number and size
of myotubes.
PPARb activation has been shown not only to increase
the number of oxidative myofibres and capillaries in skel-
etal muscle, but also to promote myonuclear accretion [43],
which is a characteristic response to exercise [44–46].
Increased myonuclear density has been found in transgenic
muscle-specific over-expressing animals, as well as in
wild-type mice treated for only 2 days with a PPARb
agonist. As mouse aging is associated with reduced PPARb
expression, and with decreased numbers of oxidative
myofibres and myonuclei, which could be partially
reversed by pharmacological PPARb activation, a potential
use of PPARb agonists for the treatment of age-related
muscle atrophy has been suggested [43].
In conclusion, CLA was here found to reduce release
into the culture medium of inflammatory factors, produced
by lung cancer cells, through activation of PPAR. In turn,
the reduced content of these factors enabled differentiation
of muscle cells, again through induction of PPAR. The
study provides insight into the anti-inflammatory and
myogenic actions of CLA, and points to its possible
application as a therapeutic agent in inflammatory disease
states, such as cachexia.
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